Alternate Day Buprenorphine Administration, Phase XII - 17

National Institutes of Health (NIH)

Status and phase: Completed; Phase 2

Conditions: Opioid-Related Disorders

Treatments: Drug: Buprenorphine

Study type: Interventional

Funder types: Other; NIH

Identifiers

NCT00000235

NIDA-06969-17

R01-06969-17

Details and patient eligibility

About

The purpose of this study is to determine if six times daily buprenorphine dose is effective in achieving 120 hour buprenorphine dosing.

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion and exclusion criteria

Please contact site for information.